Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Palantir Technologies Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.59 (market cap $4.59B), while Palantir Technologies Inc trades at $201.18 (market cap $477.68B). The key difference: Palantir Technologies Inc is far larger — about 104.1× Definium Therapeutics Inc. Common Shares's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Palantir Technologies Inc for 78 Days on average.
| DFTX | PLTR | |
|---|---|---|
Market Cap | $4.59B | $477.68B |
Volume | 2,103,937 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $48.45 | $207.18 |
52-Week Low | $10.68 | $107.27 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $3.55B | $468.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Palantir (PLTR) trades at $194.04, up 1.02% today, near its recent high and above the consensus price target of $191.69. The stock shows a bullish technical trend with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company reported robust revenue of $4.48 billion in 2025, with net income surging to $1.63 billion and a net margin of 36.3%, while recent quarters have consistently beaten EPS expectations.
Outlook remains positive driven by AI platform growth and expanding commercial customer base, but high valuation ratios (P/E of 169.9, P/S of 83.02) pose risks. Investor sentiment is buoyed by analyst buy ratings (53.84%) and partnerships like the recent Armada alliance, though competitive pressures and execution challenges are key watchpoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
